0001193125-20-252366.txt : 20200923 0001193125-20-252366.hdr.sgml : 20200923 20200923164252 ACCESSION NUMBER: 0001193125-20-252366 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200923 FILED AS OF DATE: 20200923 DATE AS OF CHANGE: 20200923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ascendis Pharma A/S CENTRAL INDEX KEY: 0001612042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36815 FILM NUMBER: 201192419 BUSINESS ADDRESS: STREET 1: TUBORG BOULEVARD 12 CITY: HELLERUP STATE: G7 ZIP: DK-2900 BUSINESS PHONE: 45 70 22 22 44 MAIL ADDRESS: STREET 1: TUBORG BOULEVARD 12 CITY: HELLERUP STATE: G7 ZIP: DK-2900 6-K 1 d31366d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2020

Commission File Number: 001-36815

 

 

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 

 

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                 Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134 and 333-225284) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On September 23, 2020, the Company announced that it had filed a Clinical Trial Notification with the Pharmaceuticals and Medical Devices Agency in Japan to initiate the Company’s Phase 3 trial of TransCon hGH (lonapegsomatropin), a long-acting prodrug of somatropin (hGH), in subjects with pediatric growth hormone deficiency, the riGHt Trial.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Ascendis Pharma A/S
Date: September 23, 2020     By:   /s/ Michael Wolff Jensen
      Michael Wolff Jensen
      Chairman and Senior Vice President, Chief Legal Officer